

## **Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria**

by Jun-ichi Nishimura, Kiyoshi Ando, Masayoshi Masuko, Hideyoshi Noji, Yoshikazu Ito, Jiri Mayer, Laimonas Griskevicius, Christoph Bucher, Florian Müllershausen, Peter Gergely, Izabela Rozenberg, Anna Schubart, Raghav Chawla, Jean-Michel Rondeau, Michael Roguska, Igor Splawski, Mark T. Keating, Leslie Johnson, Rambabu Danekula, Morten Bagger, Yoko Watanabe, Börje Haraldsson, and Yuzuru Kanakura

*Received: August 6, 2020.*

*Accepted: March 1, 2022.*

*Citation: Jun-ichi Nishimura, Kiyoshi Ando, Masayoshi Masuko, Hideyoshi Noji, Yoshikazu Ito, Jiri Mayer, Laimonas Griskevicius, Christoph Bucher, Florian Müllershausen, Peter Gergely, Izabela Rozenberg, Anna Schubart, Raghav Chawla, Jean-Michel Rondeau, Michael Roguska, Igor Splawski, Mark T. Keating, Leslie Johnson, Rambabu Danekula, Morten Bagger, Yoko Watanabe, Börje Haraldsson, and Yuzuru Kanakura. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.*

*Haematologica. 2022 Mar 10. doi: 10.3324/haematol.2020.265868. [Epub ahead of print]*

### *Publisher's Disclaimer.*

*E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.*